Order

Molecular Oncology - AML-Panel (NGS) (798)

Samples:

1 samples of 10 µl

Sample properties:

DNA solution (approx. 50 ng/µL)

Requirement for EQAS/PT according to Rili-BÄK

Parameters:

not applicable

Certificate Validity: not applicable

Not subject to Rili-BÄK

Parameters:

ASXL1 (NM_015338.6) Exon 13 Mutation(s), ASXL1 Nomenclature, CEBPA (NM_004364.5) Mutation(s), CEBPA Nomenclature, FLT3 (NM_004119.3) Mutation(s) Exon 20, FLT3 Nomenclature, IDH1 (NM_005896.4) Exon 4 Mutation(s), IDH1 Nomenclature, IDH2 (NM_002168.4) Exon 4 Mutation(s), IDH2 Nomenclature, NPM1 (NM_002520.7) Exon 11 Mutation(s), NPM1 Nomenclature, RUNX1 (NM_001754.5) Mutation(s), RUNX1 Nomenclature, TP53 (NM_000546.6) Mutation(s), TP53 Nomenclature

Certificate Validity: not applicable

Shipping Information:

Shipping not cooled

Safety Information:

Process as patient sample material

Dates:

Registration deadline:

Sample shipment:

Closing Date:

Feb. (1)	July (4)
13.11.2026	23.04.2027
12.01.2027	22.06.2027
12.02.2027	23.07.2027

EQAS/PT Experts:

Prof. Dr. Karl-Anton Kreuzer

Universitätsklinikum Köln

Innere Medizin I

Kerpener Straße 62

50937 Köln

+49 221 478 97626

karl-anton.kreuzer@uni-koeln.de

Dr. rer. nat. Eva Lorsy

Universitätsklinikum Köln

Kerpener Straße 62

50937 Köln

+49 221 478 98828

eva.lorsy@instand-ringversuch.de

back